Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

• Status: Not yet recruiting
• Trial end date: 2030-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Gabapentin

Criteria

Inclusion Criteria:

• Age 18+

• Undergoing pulmonary resection (includes metastasectomy as well as anatomic resections)

• Must have device with email capabilities for follow up survey

Exclusion Criteria:

• Requiring narcotic pain medication or Gabapentin at the time of preoperative appointment or within 30 days of surgery

• Renal impairment requiring dialysis

• Allergy to Gabapentin